Answers are grounded in this paper and cite their sources.
This study aimed to investigate the antitumor effects and underlying mechanisms of aerobic exercise combined with universal chimeric antigen receptor T (U CAR-T) cell therapy in colorectal cancer (CRC). First, CRISPR/Cas9-mediated knockout of NLRC5 and CIITA in induced pluripotent stem cells (iPSCs) was performed to generate universal iPSCs with reduced immunogenicity and enhanced resistance to immune rejection, which were subsequently induced to differentiate into T cells. A second-generation chimeric antigen receptor (CAR) targeting carcinoembryonic antigen (CEA) was then constructed and introduced into the differentiated T cells via lentiviral transduction to generate U CAR-T cells. In vitro experiments demonstrated that U CAR-T cells exhibited stable surface expression of CEA-CAR and potent, specific cytotoxicity against CEA-positive CRC cells. A CRC xenograft model was subsequently established in nude mice to evaluate the therapeutic efficacy of aerobic exercise combined with U CAR-T cells in vivo. No significant differences in body weight were observed among the groups, indicating that the treatment was well tolerated. Tumor inhibition increased in the following order: Ctrl < Ex<U CAR-T < Ex+U CAR-T, with the combined treatment showing the greatest antitumor efficacy. Immunohistochemical analysis revealed markedly increased infiltration of CD3 ⁺ , CD4 ⁺ , and CD8 ⁺ T cells in tumor tissues from the combined-treatment group. Moreover, ELISA demonstrated significantly increased levels of IL-2, TNF-α, IFN-γ, and CXCL9, whereas hematoxylin and eosin staining revealed no obvious pathological damage to major organs, including the liver and lungs. These findings suggest that aerobic exercise enhances the infiltration and activation of U CAR-T cells within the tumor microenvironment, potentially through upregulation of CXCL9, thereby alleviating immunosuppression and enhancing the antitumor efficacy of U CAR-T cell therapy. Collectively, aerobic exercise combined with U CAR-T cell therapy exhibited favorable antitumor activity and tolerability, providing experimental evidence and a potential therapeutic strategy for improving immunotherapy efficacy in CRC.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: